|
Immunogen &
Adjuvant
|
n
|
Anti-gp120
(end-point titer)
|
Anti-CD4bs
(ID50)d
|
---|
Experiment 1b
|
No Ag & IFA
|
2
|
< 20
|
< 20
|
|
CD4bs+ Env & IFA
|
4
|
> 2500
|
310 (210–470)e
|
|
CD4bs- Env & IFA
|
3
|
> 2500
|
< 20
|
Experiment 2c
|
No Ag & RIBI
|
6
|
< 100
|
< 100
|
|
CD4bs+ Env & RIBI
|
5
|
9060 (2500–12500)
|
2160 (630–5900)
|
|
CD4bs- Env & RIBI
|
5
|
> 12500 (12500->12500)
|
< 100
|
- aSera were collected two weeks after the final immunizations and tested for reactivity with recombinant gp120LAI in ELISA.
- bAll mice were B10.A, except for two BALB/c in the second group. Each animal was immunized 4x i.p. with 5 μg of antigen in IFA.
- cAll mice were BALB/c and each was immunized 5x i.p. with 5 μg of antigen in RIBI.
- dSerum dilutions that block CD4 binding to gp120LAI by 50%.
- eGeometric mean and range of the Ab levels from all mice in each group.